$LXEO
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Healthcare
Sector
Biotechnology
Industry
R. Nolan Townsend
CEO
75
Employees
$4.45
Current Price
$458.36M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $256,576.85 | 57,560 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $256,576.85 | 57,560 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 4 | $256,576.85 | 57,560 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 6 | $280,110.09 | 62,204 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 7 | $593,247.09 | 117,204 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Tamayo Louis Edward Chief Financial Officer | Sale | 4,641 | $4.49 | $20,838.09 | View Details |
| Jul 1, 2026 | Otero Jose Manuel Chief Operating Officer | Sale | 4,666 | $4.48 | $20,903.68 | View Details |
| Jul 1, 2026 | Bhalla Narinder Pal Chief Medical Officer | Sale | 22,306 | $4.42 | $98,592.52 | View Details |
| Jul 1, 2026 | Townsend Richard Nolan Director | Sale | 25,947 | $4.48 | $116,242.56 | View Details |
| May 18, 2026 | Otero Jose Manuel Chief Operating Officer | Sale | 1,302 | $5.07 | $6,606.35 | View Details |
| May 18, 2026 | Townsend Richard Nolan Director | Sale | 3,342 | $5.06 | $16,926.90 | View Details |
| Apr 6, 2026 | Townsend Richard Nolan Director | Sale | 55,000 | $5.69 | $313,137.00 | View Details |
22 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.